ADGMAdagio Medical Holdings Inc.
ADGM
Adagio Medical Holdings Inc.564
Mkt Cap
$18.77MVolume
392,793.0052W High
$2.5852W Low
$0.74PE Ratio
-0.57ADGM Fundamentals
Price
$0.841Prev Close
$0.8449Open
$0.8550D MA
$1.15Beta
0.21Avg. Volume
227,881.06EPS (Annual)
-$1.51P/B
3.26Rev/Employee
$0.00$21.89
Adagio Medical Submits Premarket Approval Application to FDA for vCLAS Ventricular Ablation System for the Treatment of Ventricular Tachycardia
Adagio Medical Holdings, Inc (Nasdaq: ADGM) (Adagio or the Company), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced the submission of its Premarket Approval (PMA) application to the U.S. Food and Drug Administration (FDA) for the...
Adagio Medical Reports First Quarter 2026 Results and Meaningful Clinical Progress
Adagio Medical Holdings, Inc (Nasdaq: ADGM) (Adagio or the Company), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced financial results...
Adagio Medical to Participate in the BofA Securities 2026 Health Care Conference
Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (Adagio or the Company), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that management...
Adagio Medical Announces Positive Pivotal Results for vCLAS Ventricular Ablation System
Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (Adagio or the Company), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today reported six month results...
Adagio Medicals ULTA Technology to Be Featured at the Heart Rhythm 2026 Conference
Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (Adagio or the Company), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that its...
Adagio Medical Receives IDE Approval from the FDA to Investigate Next-Generation vCLAS Ventricular Ablation System
Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (Adagio or the Company), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that the U.S. Food and Drug Administration (FDA) has granted Investigational Device Exemption (IDE) approval to...
Adagio Medical to Participate in the 25th Annual Needham Virtual Conference
Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (Adagio or the Company), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that management...
Adagio Medical Ultralow Temperature Ablation U.S. Pivotal Study Results to be Presented in Late-Breaking Session at Heart Rhythm Society 2026
Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (Adagio or the Company), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that the pivotal...
Adagio Medical Reports Fourth Quarter and Full Year 2025 Results
Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (Adagio or the Company), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced financial results for the fourth quarter ended December 31, 2025. Fourth Quarter and Recent Business Highlights...
Adagio Medical Announces Publication of Pre-Clinical Results for Next Generation Ventricular Ablation Catheter
Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (Adagio or the Company), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced the publication...
<
1
2
...
>
Compact View
Not available
Not available
Advertisement|Remove ads.
Latest ADGM News
ViewAdagio Medical Submits Premarket Approval Application to FDA for vCLAS Ventricular Ablation System for the Treatment of Ventricular Tachycardia
Adagio Medical Reports First Quarter 2026 Results and Meaningful Clinical Progress
Adagio Medical to Participate in the BofA Securities 2026 Health Care Conference
Advertisement|Remove ads.